Tweets
Modest IL-6 mAb benefit w/ COVID. Metanalysis 27 RCTs & 10 930 hosp COVID pts shows 28D all-cause mortality lower w/ IL-6i (vs usual care.PBO) (OR 0.86), better w/ steroids (OR 0.78). Mortality 22% w/ IL-6i vs 25% usual care. https://t.co/rTLjGMMe2g https://t.co/nz1sbKlk2E
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
How should anti-IL-6 mAb therapy be used in COVID-19 infection?
1. w/ corticosteroids
2. Early/severe pts:
3. Hospitalized on O2, but not ventilated
https://t.co/S6DT0Fsjow https://t.co/oeM8EgZk8n
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Lit review shows there are few good studies patients on the management of hospitalised gout pts. No studies have tested strategies designed to prevent gout re-admissions/flares. Better prospective studies of ULT use by hosp gout is needed https://t.co/OVkMTepa5y
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
HCQ prolongs SLE survival. Case–control study 6241 incident SLE pts compared 290 SLE dead to 502 alive controls. HCQ reduced all-cause mortality by 50% (aOR 0.50; .30–0.82) but HCQ stoppers had incr mortality (aOR 2.47) - sick stopper effect? https://t.co/JIeTJaDVPk
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
185 Lupus pts undergoing renal transplant for ESKD saw good outcomes. Pt survival = 88%, 82%, 78% & 67% (@ 1,3,5,10 yrs). Graft survival was 93%, 89%, 87% & 89% (@ 1,3,5,10 yrs). Immunosuppressive use was protective & only 2 cases of recurrent LN seen https://t.co/xgFYskeX0a
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Metanalysis of 33 clinical trials show that corticosteroids are anaglesic, especially in 1st 3 mos (mean drop VAS pain -12mm); after that benefit wanes to -8mm @3-6 mos and -6mm (95% CI, -10mm, -2mm) after 6 mos. https://t.co/IKZhqqwhPO
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Top June Tweet: Pain Persists in RA, Even Without Inflammation
One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found.
https://t.co/K8zf1pE9jM https://t.co/XwdCXnktQN
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns
https://t.co/3Q5OvHRht5 https://t.co/JLFuj5tETw
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Are you subscribed to RheumNow? Benefits include delivery of new articles right to your inbox, access to downloads and more.
Register today.
https://t.co/riyAnrRHhX
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Tofacitinib shown to work very well in ankylosing spondylitis.
@RWCSmtg @JointMD https://t.co/bx5FS9BSDZ
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Throwback Tweet: Hello 2021 and new drug price hikes - on average a 4.2% hike in over 500 drugs (past years saw an avg hike ~5%). Increases include Cosentyx 7%, Humira & Rinvoq 7.4%, Orencia 4.5%, Taltz 5%, Actemra 3%, Benlysta 5%, Xeljanz 4.9% & Cimzia 4%
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Great Gout Teaching points. Here's my 2 cards on how to Stop #gouta https://t.co/R3EhYFusKf
Dr. John Cush @RheumNow ( View Tweet )
5 years 1 month ago
